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INTRODUCTION 
 
In recent years, the role of anesthesia and its level of safety in patients 
have gained prime importance. Stable hemodynamics has become the key to 
safe and successful induction and intubation. The usual response to 
laryngoscopy and endotracheal intubation is hypertension and tachycardia.  
They cause little consequence in healthy patients, but may cause dangerous 
complications in patients with hypertension, raised intracranial pressure, 
aneurysmal vascular disease, and diseased cerebral vasculature or with 
ischemic heart disease(1). There are many strategies used to blunt the 
intubation response (2). This study compares the haemodynamic response of 
oral ivabradine and intravenous lignocaine and highlights the advantage of 
ivabradine over lignocaine. 
     Ivabradine is a cardio tonic agent. It is a extremely selective inhibitor 
of funny current channel. [If].  This channel inhibition results in diminution in 
the slope of spontaneous depolarization, leading to prolongation of the time 
interval between consecutive action potentials in the SA node,  thus decreasing 
the heart rate. This drug combine with the intracellular place of the „If‟ channel 
and hinders it in a dose and voltage dependent manner. As the binding site is 
situated intracellular, ivabradine needs an open „If‟ channel to reach to its 
required site. Ivabradine reduces the heart rate without altering hemodynamics 
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in unhealthy patients. This drug can be used in both hypertensive & 
normotensives (3) . 
 Lignocaine is an amide group of local anesthetic . It is used in treatment 
of patients with ventricular dysarrthmias and as prophylaxis in treatment of 
ventricular tachyarrthmias especially in connection with myocardial infarction 
and mechanical irritation of cardiac fibers. The principal metabolite of 
lignocaine is monoethylglycine xylidide.  This metabolite has approximately 
80% of the activity of lignocaine for protection against cardiac dysarrythmias. 
Lignocaine prevents conduction of nerve impulse (conduction blockade). It 
blocks passage of sodium ions thru ion selective sodium channels in nerve 
membrane. The Na+ channel is a definite receptor to lignocaine. 
Intravenous lignocaine is used to blunt raises in heart rate, B.P, 
intracranial &intraocular pressure (4). These comprise a direct myocardial 
depressant effect, a peripheral vasodilating effect(5) .This study aims to 
compare the hemodynamic response of oral ivabradine and intravenous 
lignocaine during induction and intubation in ASA-I patients.  
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ANATOMY 
ANATOMY OF AIRWAY (6) (7) 
.           
 There are two openings to the human airway. 
 Nose – continues  as  nasopharynx 
 Mouth –continues as oropharynx. 
 These passageways are parted anteriorly by the palate. They join 
posteriorly in the pharynx. 
 
PICTURE.1. ANATOMY OF AIRWAY (6) 
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Pharynx (6),(7): 
The pharynx is a U shaped wide muscular conduit.  It starts from the 
base of the skull and ends at the cricoid cartilage which is at the entry to the 
oesophagus. 
It opens anteriorly in to 
 Nasal cavity-nasopharynx 
 The mouth-oropharynx 
 The larynx-laryngopharynx  
The nasopharynx 
             The nasopharynx lies behindhand the nasal cavity and above the soft 
palate. It interconnects with the oropharynx over the pharyngeal isthmus. On 
the lateral wall lies the pharyngeal opening of the pharyngotympanic 
(Eustachian) tube. 
The oropharynx 
The oral cavity continues with the oropharynx via the oropharyngeal 
isthmus, surrounded by the palatoglossal arches, the soft palate and the 
dorsum of the tongue. The oropharynx itself begins from the soft palate ends 
at the tip of the epiglottis.  
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The laryngopharynx  
 The third portion of the pharynx starts from the tip of the epiglottis and 
ends at the inferior border of the cricoid cartilage at the level of C6 vertebrae. 
Oropharynx and laryngopharynx separated functionally by the epiglottis at the 
floor of the tongue the epiglottis avoids aspiration by wrapping the glottis 
while swallowing. 
Muscles of the pharynx 
 The   muscles of the pharynx are  
 superior  constrictor- stylopharyngeus 
 middle  constrictor-  salphingopharyngeus and  
 inferior constrictor - palatopharyngeus 
LARYNX: 
       It lies against the C4, C5, C6 cervical vertebrae. Larynx comprises a 
context of articulating cartilages, interconnected by ligament.     
The laryngeal cartilages  
      There are nine cartilages. 3 unpaired cartilages:  
1. Thyroid cartilage 
2. Cricoid cartilage 
3. Epiglottis 
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    3 paired   cartilages 
1. arytenoid   cartilage 
2. corniculate cartilage 
3. Cuneiform cartilage.                          
The laryngeal ligaments  
These are divided into 
 the extrinsic  ligaments  
 The intrinsic ligaments. 
The extrinsic ligaments: 
1  The thyro-hyoid membrane-starts from the upper edge of the 
thyroid cartilage to the hyoid bone.  
2  The crico-tracheal ligament- which connects the cricoid and first 
tracheal ring. 
3  The crico-thyroid ligament- connects the thyroid cartilage with 
the cricoid cartilage.  
4  The hyo-epiglottic ligament- lies between the epiglottis and the 
body of the hyoid.  
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The intrinsic ligaments: 
  These are capsules of the synovial joints in between the arytenoid and 
cricoid cartilage& in-between the thyroid and cricoid cartilages. These are the 
fibrous structure of the inner larynx. 
Muscles of the larynx 
 They are divided into 
 The extrinsic group- connects the larynx to its neighbors, 
 The intrinsic group- accounts for the movement of the laryngeal 
cartilage.  
The extrinsic muscles: 
 sternothyroid, 
  thyrohyoid  
 The inferior constrictor of the pharynx. 
  Some fibers of stylopharyngeus &palatopharyngeus go forward to the 
posterior edge of the thyroid cartilage. 
1  The sternothyroid muscle-starts from the posterior part of the 
manubrium end at the oblique line situated on the lateral side of 
the thyroid lamina. It lowers the larynx. 
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2  The thyrohyoid muscle- goes upwards starting from oblique line 
of thyroid lamina to the lower edge  of the greater horn of the 
hyoid. It uplifts the larynx. 
3  The inferior constrictor starts from the oblique line of the thyroid 
lamina, as a tendinous arch above the cricothyroid muscle and 
from the sideways of the pharynx. This is a constrictor of the 
pharynx.  
Muscles involved in the indirect movement of the larynx are   
 Indirect elevators are- 
 mylohyoid, 
 stylohyoid  
 geniohyoid 
Indirect depressors  
 sternohyoid  
 Omohyoid. 
Intrinsic muscles of the larynx  
 Posterior cricoarytenoids muscle 
 Lateral cricoarytenoids muscle 
 Interarytenoid muscles 
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 Thyroarytenoid muscle 
 Vocalis 
 Cricothyroid muscle 
The actions of the intrinsic laryngeal muscles 
  1]  Abductors of the cords: posterior cricoarytenoids; 
  2]  Adductors of the cords: lateral cricoarytenoids& interarytenoid 
  3]  Sphincters to vestibule: aryepiglottics& thyroepiglottis 
4]  Regulators of cord tension: cricothyroid are tensors of cord, 
Thyroarytenoid (relaxation of cords) & Vocalis (fine adjustment). 
SENSORY NERVE SUPPLY OF UPPER AIRWAY (8): 
 
PICTURE 2.SENSORY NERVE SUPPLY OF UPPER AIRWAY  
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The pharynx:  
Sensory nerve supply: 
Glossopharyngeal nerve innervates  
 the posterior third of the tongue 
 the fauces  
 tonsils,  
 anterior epiglottis  
 Parts of the pharynx with visceral sensory innervation. 
Motor supply:  
 Efferent supply- Vagus nerve thru its pharyngeal branch. 
The larynx:   
 Sensory nerve supply: 
   The internal laryngeal Nerve-    It is a branch of the superior laryngeal nerve. 
                          From the posterior epiglottis to the vocal 
     cords .   
   The recurrent laryngeal Nerve - the larynx below the vocal cords   
     the trachea.  
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Motor supply:  
    Recurrent Laryngeal Nerve -     Intrinsic muscles of the larynx except the 
     cricothyroid  muscles.  
 
PICTURE.3. NERVE SUPPLY OF LARYNX (7): 
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PHYSIOLOGY OF INDUCTION AND INTUBATION 
Mechanism of hemodynamic responses during induction (9),(10),(11) 
 Intravenous induction of general anesthesia is often associated with 
hypotension. Several mechanisms have been thought responsible for the 
decrease in blood pressure and are classified into two broad categories namely 
1)  Direct effects 
2)  Indirect effects 
Direct effects (11):  
 This occurs primarily due to the effect of drug on the contractility of 
the myocardium. Measurement of this intrinsic myocardial contractility is 
more accurately performed in in-vitro models. Possible mechanism for this are 
probably due to interference with the calcium transport across myocardial cells 
and a decrease in neural nitric oxide synthetase activity. 
Indirect effects (11): 
 Preload 
 Afterload 
 Sympathetic activity 
 Baroreflex activity 
 Central nervous system activity 
22 
 
 Of all the above mentioned factors, the baroreflex activity is the single 
most important point in induction .Basically this reflex is started by stretch 
receptors known as baroreceptor /pressure receptors. They are situated in the 
walls of the huge systemic arteries .A increase in pressure in systemic arteries 
will stretch the baroreceptors and affect them to conduct signals into CNS and 
response signals will send back via the ANS to the systemic circulation to 
decrease arterial pressures towards the normal level. 
Physiological anatomy of baroreceptors and their innervations 
 These are spray variety of nerve terminals lying on the wall of the 
vessels that are aroused when stretched. Some baroreceptors are sited on the 
wall of nearly all single big blood vessel of the thoracic and neck region. They 
are extremely abundant on the wall of both internal carotid artery somewhat 
directly above the carotid bifurcation. This area is recognized as carotid 
sinus& wall of aortic arch.   
Response of  baroreceptor to pressure 
 The carotid baroreceptors, which are not aroused by pressures between 
Zero to Sixty mm of Hg, they react gradually and hastily and reach a high 
pressure of 180 mm of Hg. The response to the arch of aorta baroreceptors are 
alike carotid baroreceptors excluding that they will respond at pressure limits 
of around 30 mm of Hg or more .Baroreceptors react enormously to variations 
in arterial blood pressures. Indeed the degree of impulse firing rises 
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throughout systole and reduces yet again during diastole. Moreover the 
baroreceptors react very rapidly to sudden changes of BP somewhat to static 
pressures. 
Reflex pathway of baroreceptor system 
 Transmission of signals from both carotid sinus via very small 
Herrings nerve to glossopharyngeal Nerve. Then they reach tractus solitaries 
in medulla oblongata .Secondary impulses impede the center of 
vasoconstrictor within the medulla and stimulate the vagal centre. The end 
results are  
 Vasodilatation throughout peripheral circulation 
 Decreased heart rate &strength of myocardial contraction 
 Conversely, low pressures have a contrary effect producing the pressure 
to augmentation back towards basal. 
Mechanism of haemodynamic responses during Intubation (11)(12) 
         Endotracheal intubation is associated with a temporary escalation in 
blood pressure and rate of the heart and with an increase in the plasma 
concentration of epinephrine. All studies have shown that haemodynamic 
response which occurs during intubation is mainly due to stimulation of 
sympathetic nervous system. Exact cause for the haemodynamic response is 
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not known. It could be because of activation of the Somato-visceral reflex due 
to stimulation of the base of the tongue and epiglottis. 
Basic pathways involved in medullary control of heart rate and blood 
pressure (9)(10) 
 
PICTURE.4. MEDULLARY CONTROL OF HEART RATE AND 
BLOOD PRESSURE -BASIC PATHWAY 
 
Somato-visceral reflex: 
  Provocation   of   proprioceptors situated on the base of the tongue 
during intubation induces surge in pressure changes and rate of the heart. 
Subsequent   attempts   recruit additional receptors that further augment 
hemodynamic and catecholamine   concentration. Probable   pathway for   
Somato visceral reflex resulting in hemodynamic changes is given below. 
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Afferent pathway 
  The afferent fibers mainly arise from the various receptors which are 
present in the larynx and trachea. The various receptors are pain receptors 
carried by unmyelinated C fibers, touch receptors which are more in the lower 
half of true vocal cords, chemical receptors and thermal receptors mainly in 
the supraglottic and epiglottis area, joint and pressure receptors and stretch 
receptors. The afferent response from these receptors (general visceral 
afferent) is transmitted along the Vagus nerve to the tractus solitaries. 
Central-vasomotor center: 
 Nerve fibers from   tractus   are projected into the superficial 
ventrolateral reticular area of reticular activating system .This area is mainly 
concerned with cardiovascular, baroreceptors, chemoreceptors and respiratory 
reflexes and probably forms the vasomotor center. 
Efferent pathway: 
  Reticulospinal efferent from this ventrolateral reticular region 
(vasomotor center) terminate bilaterally on the preganglionic neurons of 
sympathetic system in the thoracic spinal nerves. Along sympathetic nerve it is 
distributed to all the vessels except capillaries, precapillaries, precapillary 
sphincter and Meta arterioles. 
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Other probable pathways 
A .  Activation of pain pathway 
 Pain impulse from the respiratory tract and oral cavity are mainly 
transmitted by unmyelinated C fibers .Pain pathways from the head and neck 
synapse in  spinal sensory nucleus of trigeminal nerve. The fibers from here 
cross to the opposite side. Here they divided into two pathways.   One ascends 
in ventral trigeminal-thalamic tract and end in thalamus, other fibers pass into 
the reticular formations where they synapse with ascending reticulo-thalamic 
fibers and end in thalamus. Few example, stimulus of motor cortex rouses 
center of vasomotor by the signals conveyed downwards into the 
hypothalamus and thereafter into the center of vasomotor. Stimulus of 
vasomotor center causes increase in heart rate and blood pressure. Stimulation 
of hypothalamus will also activate hypothalamo -pituitary axis as part of stress 
response. 
B.  Hypothalamo pituitary adrenal axis stimulation as a part of these 
stress response: 
       The afferent response from the upper airway larynx and trachea is 
transmitted along the vagus nerve to the tractus solitarious. Nerve fibers from 
the tractus solitarious are projected into the superficial ventrolateral area of 
reticular activating system .Fibers from here ascend and synapse in supraoptic 
and Para ventricular areas of the hypothalamus. Excitation of these cells 
causes release of vasopressin from neurohypophysis. Medullary noradrenergic 
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cell groups A1and A2 in the ventrolateral reticular area also innervate directly 
or indirectly the median eminence and control the release of ACTH which in 
turn acts on adrenal cortex to release cortisol. This cortisol in turn acts on the 
adrenal medulla to secrete catecholamine. These catecholamines in turn act on 
the cardiovascular system and cause alteration in blood pressure. 
Neural regulation of the circulation (9),(10) 
         The nervous system switches the circulation virtually via the ANS, 
mainly by sympathetic nervous system. It controls the cardiovascular system 
by two mechanisms: 
1)  Through definite sympathetic nerves which supply the blood 
vessels and heart. 
2)  Through   catecholamine release. 
Cardiac innervation:  
The efferent preganglionic cardiac sympathetic fibers arise in the upper 
four or five thoracic spinal segments, while the parasympathetic is from the 
Vagus. Impulses from the nor-adrenergic sympathetic nerves supply of the 
heart raise rate of heart and force of heart contraction. They also impede the 
end result of vagal stimulus. Impulse   conduction from cholinergic vagal heart 
fibers reduces heart rate. A reasonable quantities of tonic release takes place in 
the heart sympathetic nerves at resting conditions. But there are worthy pact of 
tonic vagal release in humans 
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Innervation of the blood vessels:                                                                                                            
 Though the arterioles and the additional resistant vessels are utmost 
compactly innervated, capillaries and venules that contains smooth muscles 
and get motor nerve supply from the sympathetic part of the ANS. Regulation 
of tissue blood flow and arterial pressure are maintained through the nerve 
fibers of resistance blood vessels. Blood vessels of all parts of the body are 
innervated by nor adrenergic fibers. They are vasoconstrictor in nature. The 
resistance blood vessels of the skeletal muscles are innervated by both 
cholinergic and nor adrenergic nerve fibers.  
Vasomotor control: 
 Sympathetic nerve fiber constricts arterioles and veins and raise heart 
rate and stroke volume in a stimulant manner, blood pressure is modified by 
variations in the frequency of this tonic liberation. Spinal reflex action affects 
pressure in the blood vessels, but the chief regulation of blood pressure is 
exercised by collections of neurons in the medulla oblongata, are at times 
called as the vasomotor area or vasomotor center. 
 Factors affecting the activity of the vasomotor are in the medulla. 
1. Direct stimulation 
 Carbon dioxide 
 Hypoxia 
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 2.  Excitatory inputs 
 From the cortex via hypothalamus 
 From pain pathways and muscles 
 From chemoreceptors of carotid& aortic bodies 
3.  Inhibitory inputs 
 From the cortex thru hypothalamus  
 From lungs 
 From carotid, aortic and cardio-pulmonary baroreceptors. 
Nerve supply to adrenal glands (11) 
      Sympathetic nerve fibers innervating the adrenal glands arise from the 
T8-L1 segments. Many preganglionic fibers from these segments pass through 
the paired paravertebral ganglion to form the splanchnic nerves; most do not 
synapse until in celiac ganglion, whereas others innervate the adrenal medulla 
directly. Majority of the fibers to adrenal gland contains myelinated nerve 
fibers and few unmyelinated nerve fibers. Adrenal gland receives larger 
autonomic supply than any other organ. Preganglionic fibers directly synapse 
with large chromaffin cells in adrenal medulla. Stimulation of these fibers 
directly cause release of catecholamines, thereby they act similar to post 
ganglionic fibers. 
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Coronary perfusion (11): 
 Coronary perfusion is distinctive in that it has intermittent to some 
extent than continues, as in other structures, during contraction, pressure in 
intra myocardium of the LV reaches systemic blood pressure. The potency of 
the left ventricle contraction virtually occludes the intramyocadial portion of 
the coronary arteries actually; flow of blood might transiently inverse in 
epicardial blood vessels. In the last part of diastole, left ventricular pressure 
ultimately surpasses right atrial pressure. Therefore pressure of coronary 
perfusion is commonly decided by the variation between aortic pressure and 
ventricular pressure, left ventricle is getting blood supply completely during 
diastole. In disparity the right ventricle is getting blood supply both during 
systole and diastole.  Furthermore, as a element of myocardial blood flow, 
arterial diastolic pressure is added significant than mean arterial pressure.  
Coronary perfusion pressure = Arterial diastolic pressure - Left ventricular end 
diastolic pressure 
 Decrease in aortic or increase in L.V end diastolic pressure could 
reduce pressure of coronary perfusion. Increase in rate of heart also decreases 
perfusion of the heart, since unduly more reduction in diastolic time as the rate 
of the heart increases. As it is exposed to the maximum intramural pressure 
during systole, the endocardium has a predisposition to ischemia during 
reduction in pressure coronary perfusion. 
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Regulation of coronary blood flow (11): 
   Blood supply of heart is normally equals myocardial metabolic needs. 
In the normal adult man and at rest blood flow to the heart is around 250 
ml/min at rest. The myocardium controls its individual blood flow 
meticulously between perfusion pressures of 50 mm of Hg -120 mm of Hg, 
afar this range, circulation becomes increasingly depends on pressure. 
 Under normal circumstances, fluctuations in blood flow are completely 
due to variants in coronary artery tone in reaction to metabolic need. Hypoxia 
whichever directly or indirectly over the discharge of adenosine leads to 
coronary vasodilatation.   Autonomic influences were commonly weak. Both 
adrenergic receptors   α1&β 2 are exists in coronary arteries. The α1 
adrenergic receptors are chiefly positioned on great epicardial vessels, whereas 
β2 adrenergic are generally located on the smaller intramuscular & 
subendocardial blood vessels. Sympathetic stimulus usually rises the 
myocardial blood flow owing to an rise in myocardial need and a majority of 
β2 receptor stimulation. Parasympathetic possessions on coronary vasculature 
are usually slight and are faintly vasodilatory. 
Regulation of myocardial oxygen supply- demand (11): 
 Myocardial oxygen need is ascribed by many processes  
 Basal metabolism -20% 
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 Electrical activity- 17 
  Blood volume work 
  Pressure work (64%).  
Usually, the myocardium abstracts more oxygen from the blood (65%) 
compared to other tissues of the body (25%). The coronary sinus oxygen 
saturation is usually 30%. Thus when demands by the myocardium are 
increased, the oxygen extraction cannot be augmented as occurs in others parts 
of the body. Thus the needs can be met with only by increasing the blood flow 
to the myocardium. 
Factors influencing myocardial oxygen supply-demand balance (11): 
  Blood supply 
 Rate of heart 
 Time for diastole 
  Coronary perfusion pressure 
 arterial diastolic blood pressure 
 left ventricular end diastolic pressure 
 arterial oxygen content(Cao2) 
 Pao2        
 hemoglobin content 
 Coronary vessel diameter 
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 Demand 
 Basal requirements 
 Heart rate 
 Tension in the wall 
o preload 
o afterload 
o Contractility 
Mechanism of intubation response 
 The exact mechanism of intubation response is indefinable, but it 
involves both a sympathetic and parasympathetic systems. The net effect is 
temporary taking place 30 seconds after intubation and maintained for less 
than 10 minutes (13).  
Sympathetic reflex: 
 The sympathetic reflex is a polysynaptic pathway with the involvement 
of glossopharyngeal and Vagus nerve creating the afferent arc to the 
sympathetic nervous system thru the brain stem and spinal cord. This will lead 
to profound autonomic response at the efferent end. It includes augmented 
firing of the cardio-accelerator fibres and discharge of adrenergic mediators 
like norepinephrine, epinephrine &vasopressin. The end effect is hypertension, 
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tachycardia, and raise in pulmonary artery wedge pressure &decline in 
ejection fraction. 
Parasympathetic reflex: 
  It is a monosynaptic pathway & is seen often in children. It may occur 
in adults also. The response is mediated by augmented vagal tone at Sino- 
atrial node (14). 
  The haemodynamic response to laryngeal &endo- tracheal intubation is 
temporary. In many of the patients supposed to be of diminutive consequence. 
In patients with coronary artery disease, raised blood pressure, increased intra 
cranial and intra ocular pressure it might related with myocardial ischemia& 
infarction, dysrhythmias, heart failure, pulmonary oedema& intra cranial 
haemorrhage (15). The procedure of intubation consists of different phases 
and these change the haemodynamic responses uniquely. Endotracheal 
intubation comprises of two phases: 
1. Direct laryngoscopy  
2.  Introduction of endotracheal tube through the vocal cord & trachea 
(16).   
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PHARMACOLOGY OF IVABRADINE 
 
Ivabradine Hydrochloride (17): 
Generic Name:    Ivabradine   Hcl. 
Introduction:      
 It is a „pure‟ heart rate lowering drug. It has been introduced recently 
as an alternative to β blockers. It is a cardio tonic drug .Ivabradine, the first 
selective & specific inhibitors of the funny current channel. Ivabradine affords 
reduction in heart rate without changing myocardial contractility of 
myocardium.  It is useful for the symptomatic relief of chronic stable angina in 
persons with normal rhythm who were intolerant to β blockers. 
Chemical Name:  
 3(3-{[(7S)-3,4-dimethoxybicyclo[4.2.o] octa-3, 5-trien-7-yl) methyl 
amino}propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepine-2-
one,hydrochloride 
Chemical formula: C27H36N2O5 
Structural formula: 
                               /   
   PICTURE.5. STRUCTURAL FORMULA OF IVABRADINE 
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Molecular Weight: 468.585 g/mol 
Physical form:  White to pale yellow powder 
Solubility:  
 It is readily soluble in water,DMSO, methanol and methylene chloride 
and ethanol.  It is soluble in acetone to some extent. 
Category:  
 Used to treat symptoms of long standing stable angina, adults with 
coronary artery disease with normal sinus rhythm. This drug is also used in 
patients who are contraindicated or intolerance to β blockers. Ivabradine is 
also used in symptomatic treatment of tachycardia. 
Stability and storage:   
 Store at temperature not exceeding 30 degree centigrade 
Mechanism of action (17):  
 The only significant action of ivabradine is blockade of cardiac 
pacemaker (Sino-atrial) cell „f‟ channels. The „funny‟ cation channels are 
present in the S.A node. The If channels that open during early part of slow 
diastolic (phase 4) depolarization. The resulting inward current (If) determines 
the slope of phase 4 depolarization. Selective blockade of If current by 
ivabradine results in heart rate reduction without altering electrophysiological 
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or negative inotropic or negative lucitropic (slowing of myocardial relaxation) 
effect. Heart rate reduction decreases cardiac O2demand and prolongation of 
diastole tends to improve myocardial perfusion (O2 supply)(18),(19). 
PHARMACODYNAMICS:  
  Ivabradine decreases heart rate about 10 beats per minute in the course 
of exercise &at resting condition. It will lead to decrease in myocardial 
oxygen usage and work load. Ivabradine do not affect intracardiac 
contractility, conduction and myocardial contractility. This drug mainly 
reduces   the frequency of angina attacks as effective as β blockers and reduces 
short acting nitrates consumption along with β blockers. 
PHARMACOKINETICS: 
Absorption:  
 Ivabradine is quickly and entirely absorbed after oral intake. It reaches 
peak plasma concentration in 60 minutes in fasting conditions. Food delays its 
absorption. 
Distribution:  
 It binds 70% to plasma protein .The Cmax is 0.22 µg/ml.Volume of 
distribution -1001. 
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Metabolism:   
 Bioavailability of Ivabradine is 40%.Metabolised by liver and GIT by 
CYP3A4 oxidation. 
Elimination:  
 The half- life of Ivabradine is about 120 minutes in serum. Renal 
clearance - 70%. The total clearance is about 400ml/min. Excretion of 
metabolites occurs via feces and urine. And about 4% excreted unchanged in 
urine after oral administration. 
Indications  
 chronic stable  heart failure  
  stable angina                                
  Intolerant to to β blocker 
  Contraindication  to β blockers    
  inappropriate sinus tachycardia.    
Contraindications:                                                                                                                              
 Sick sinus syndrome 
  Hypertension 
  Stroke 
  Liver failure 
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  Renal failure 
   Runny nose 
 Pregnancy and lactation 
Should not be used along with CYP3A4 like azole antifungal, 
macrolide antibiotics, nafazodone & antiretroviral nelfinavir and ritonavir. 
Concomitant use of verapamil and diltiazem 
Adverse effects:  Heart:  
 Bradycardia 
 Palpitations 
 1 degree AV block. Ventricular extra systoles 
 Difficulty in breathing  
 Giddiness 
 Central nervous system: Headaches, dizziness 
 Eyes:   Luminous phenomenon- sensations of heightened brightness 
in a fully maintained visual field.  This is due to If channel block 
situated in the retina. 
 Gastro intestinal   tract: Nausea, vomiting and constipation      
 Musculo skeletal: muscle cramps and weakness                        
Dose: Initially 5 mg BD, increase if needed to 7.5 mg BD, 
Elderly 2.5 mg BD. 
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PHARMACOLOGY OF LIGNOCAINE  
LIGNOCAINE HYDROCHLORIDE 
                                                                                                                                                            
History 
Lignocaine is the first tertiary amide–type local anesthetic drug. It was 
first synthesized in 1943(20),(21)(22).In early days, it was named as 
'xylocaine'. Lignocaine was first synthesized by Nils Lofgren in Sweden.  
Bengt Lundqvist, who executed the first injection anesthesia on himself 
(20). It came to market in 1949. 
It is currently most widely used LA. It is a versatile LA, good both for 
surface applications well as injection .It is available in a variety of forms. 
Injection of Lignocaine surrounding a nerve will block impulse conduction 
within 3 min and produces anesthesia & is more intense and longer lasting. 
Vasodilatation occurs at the injected area. It is useful for surface application, 
infiltration, nerve block, epidural, spinal and intravenous regional block 
anesthesia(17). 
Chemical Name: 
 2-(diethyl amino) - N-(2, 6-dimethylphenyl) acetamide 
Chemical Formula:  C14H22 N20 
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Structural Formula: 
 
 
PICTURE.6.STRUCTURE OF LIGNOCAINE 
Molecular weight : 234.34 g/mol 
Melting point : 68 degree (154F) 
Mechanism of action (17) 
Lignocaine act mainly by inhibiting sodium influx through voltage-
gated sodium channels in the neuronal cell membrane. Once the entry of 
sodium is blocked in to the cell, action potential will not rise &there will be no 
signal conduction. The receptor site for local anesthetic is found at the inner 
lot of the NA channel& this drug combine with this channel in activated state. 
The time taken for the onset of neuronal blockade was quicker in neurons. 
This action is denoted as dependent blockade. 
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Lignocaine is a weak  base. They are formulated by means of 
hydrochloride salt as to make them water-soluble. At equal pH& pKa, the 
ionized as well as unionized forms of the particle exist in equal quantities. The 
unionized base disseminates readily across cell membranes. As soon as the 
local anesthetic drug is ionized and in equilibrium it will not go out of the cell 
membrane. This action is called by means of "ion-trapping". When the local 
anesthetic in ionized form, it binds to the LA binding site on the inner portion 
of the sodium channel at the cytoplasmic end. Majority of local anaesthetic 
drugs act on the inner side of the cell membrane. Local anesthetic drug should 
enter the cell membrane when in non-ionized state.  
 
PICTURE.7. SITE AND MECHANISM OF ACTION OF LOCAL 
ANAESTHETICS (17) 
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PHARMACOKINETICS 
Bioavailability: 
35 % (oral) 
           3 % (topical) 
Distribution:  
 The volume of distribution is 1.1-2.1 l/kg. About 60-80% circulates 
bound to the protein alpha1 acid glycoprotein. 
Metabolism:  
 Lignocaine 95% metabolized in the liver-95%.  Dealkylation chiefly by 
CYP3A4.It will form active& inactive metabolites namely monoethylglycine 
xylidide and   glycine- xylidide. Active form has a longer half compared to 
lignocaine. It  is a   weak NA channel blocker. 
Onset of action: within 1.5 min (i.v) 
Duration of action:  
 10minutes to 20 minutes (IV) 30 minutes to 180 minutes (injection) 
Elimination:  
The elimination half-life- 1.5to 2 hours. . It is excreted (90% as 
metabolites) & 10% as unchanged drug in the urine (24). 
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Dosage and administration:  
 “Lignocaine is commonly used in the formula of lignocaine 
hydrochloride. Preparations of Lignocaine are      
 Injected local anesthetic     
 Dermal patch (sometimes combined with prilocaine in a eutectic 
mixture) 
 I.V. injection 
 I.V. infusion 
 Intra osseous  Injection 
 Nasal spray with phenylephrine 
 Oral “viscous lidocaine" or abbreviated "lidocaine visc" or 
"lidocaine Hcl visc"; used as teething gel) 
 Oral solution 
 Topical gel  
 “Topical liquid” 
 Lidocaine Hcl 2% jelly, combined with hypromellose, to anesthetize 
and lubricate the urethra, etc., for inserting a catheter or instrument 
 Topical patch (lidocaine 5%),  
 Over the counter patch (lidocaine 4%) since 2015. 
 Topical aerosol spray 
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 Inhaled by nebulizer 
 Ear drops” 
USES OF LIGNOCAINE(25),(260:      
Regional Anesthesia:          
 topical or surface anesthesia       
 local infiltration         
 peripheral nerve block       
 intravenous regional anesthesia (Bier block )     
 epidural anesthesia         
 spinal (subarachnoid) anesthesia.       
Analgesia 
 The administration of I.V.(lidocaine) to provide analgesia is limited.  In 
addition to attenuating ventricular cardiac dysrhythmias, the I.V.Lignocaine 
will raise the defibrillation threshold.   
Suppression of Generalized Tonic-Clonic Seizures 
Anti-inflammatory Effects 
  It is useful in modifying perioperative inflammatory injury 
Bronchodilation 
 Inhaled lidocaine blunt histamine-induced bronchospasm .It enhances  
airway anesthesia  
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Tumescent Liposuction 
 Infiltration of large volumes of diluted lidocaine around 0.05% to 
0.10%with epinephrine (1:100,000) the subcutaneously. Lignocaine the dose 
ranges from 35 -55 mg/kg .This is known as mega dose lignocaine. 
“Lignocaine toxicity is the commonest complication in tumescent liposuction. 
Heart arrhythmias 
Lignocaine is classified as-1b antiarrhythmic type of drug. Intravenous 
Lignocaine is indicated in the treatment of ventricular arrhythmias associated 
with acute myocardial infarction , digoxin  poisoning due to digoxin 
and  cardio version or the conditions in which amiodarone was not available or 
could not be used.   
“Intravenous or topical administrations of lidocaine have been used 
with variable success to blunt hemodynamic response to tracheal intubation & 
extubation and suppress cardiac dysrhythmias”. Instrumentation of the upper 
airway will result in coughing, constriction of the bronchus and additional 
airway responses. I.V. Lignocaine effectively depresses airway reflexes due to 
instrumentation (29).  This action is mediated by decreasing c movement of 
calcium   in the smooth muscle cells of the airway. 
 “Doses of intravenous lignocaine from 2 to 2.5 mg/kg are needed to 
consistently blunt hemodynamic and airway responses to tracheal 
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instrumentation. Intravenous lignocaine is also effective for attenuating 
increases in intraocular pressure, intracranial pressure, and intra-abdominal 
pressure during airway instrumentation.
 
Attenuation of all these responses may 
be beneficial in selected clinical situations (e.g., corneal laceration or 
increased intracranial pressure)” (27), (28). 
Insensitivity (30): 
 Relative insensitivity to lignocaine is genetic. 
  Attention deficit hyperactivity disorder - hypokalemic sensory 
overstimulation. 
  In dental anesthesia- unexpected positions of nerves.  
 Ehlers-Danlos syndrome 
 Adverse effects: 
 Allergic reactions  
 Systemic toxicity  
Allergic Reactions (31)        
  Allergic reactions are infrequent and  less than 1% .  
Cross-Sensitivity 
 Cross-sensitivity amongst local anesthetics was due to the shared 
metabolite para-aminobenzoic acid. 
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Systemic Toxicity (32) 
 Systemic toxicity occurs due to excess concentration of local anesthetic 
drug. CNS symptoms generally occur when blood plasma concentrations were 
low. Cardiovascular effects usually manifests at higher concentrations, even 
though cardiovascular system may collapse at lower concentrations. 
Central Nervous System  
 At low plasma concentrations - numbness of the tongue and 
circumoral tissues  are because of delivery  of L.A. to vessel rich 
tissues. Central nervous system excitation first to occur. 
  At higher plasma concentrations - skeletal muscle twitching‟s 
(tonic-Clonic seizures) & CNS depression. 
  Neurotoxicity 
 Transient Neurologic Symptoms 
 Cauda Equina Syndrome 
 Anterior Spinal Artery Syndrome 
Cardiovascular System 
      Toxic effects of high plasma concentrations towards CVS are more 
resilient than the CNS. 
 Fall in blood pressure 
 Reduction in heart rate 
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 Dysrhythmias 
  Facial flushing 
  Decreased venous return 
  Pulmonary edema 
 Cardiac arrest  
Respiratory System:  
 Bronchoconstriction 
 Difficulty in breathing 
  Reduced respiration 
 Respiratory arrest 
Gastrointestinal System:  
 perception of metallic taste 
 nausea &vomiting 
Ears  - Tinnitus 
Eyes:     
 Burning sensation in the eyes  
 Congestion of conjunctiva 
 Corneal ulceration 
 Diplopia 
 Corneal opacity 
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Methemoglobinemia 
Ventilatory Response to Hypoxia 
Hepatotoxicity 
Dysphoria 
Dose-Dependent Systemic Effects of Lidocaine(26) 
PLASMA CONCENTRATION  
(µg/mL) 
EFFECT 
1–5 Analgesia 
5–10 Lightheadedness 
Tinnitus 
Numbness of tongue 
10–15 Seizures 
Unconsciousness 
15–25 Coma 
Respiratory arrest 
>25 Cardiovascular depression 
 
Interactions(33) 
 Drugs that increase CYP3A4 and CYP1A2  enzyme induction 
 .Drugs that precipitate Methemoglobinemia   
  Dronedarone  
  Liposomal morphine   
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Contraindications: 
Absolute contraindications: 
 2degree heart block /3 degree without pacemaker 
 S.A Nodal block (Severe) without the presence of  pacemaker 
 H/O  reactions caused by amide group of local anesthetic drugs 
 Hypersensitivity reactions related to corn food products 
 Adams Stokes syndrome  and W-P-W syndrome 
 Concomitant intake of drugs like quinidine,  flecainide, disopyramide, 
procainamide 
Exercise caution with: 
 Hypotension not related to arrhythmia 
 Reduced heart rat 
 Accelerated idioventricular rhythm 
 Old patients 
 Deficiency of pseudo choline esterase enzyme 
 “acute intermittent porphyria” 
 Impairment of liver function –patients  with reduced hepatic function 
might have an adverse reaction due to  repetitive administration of 
lignocaine  
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Over dosage: 
Disproportionate   administration of  
 Topical  
 Parenteral routes, 
 unintentional oral intake of topical preparations  
 Accidental  I.V. injection  
 prolonged use of tumescent anesthesia  
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REVIEW OF LITERATURE 
 
 1) C. G. Raghu ram, Deep raj Singh, Aditya Vikram Kabra (1) in 
(2014 )evaluated the effect of oral ivabradine on the hemodynamics during  
intubation in patients undergoing surgical procedures under general 
anesthesia& conducted in 50 ASA- I adult patients  in two groups. . Received 
oral Ivabradine 5mg one Tab. at 9.00 pm on the evening before the day of 
surgery and another one 5mg tab one hour before intubation& placebo. 
Hemodynamic variables were recorded from pre-operative period to 10 
minutes after intubation. : There were no significant escalation in the 
hemodynamic changes in during laryngoscopy and orotracheal intubation in 
the Test group, compared to the control group . Minimal raise also returned to 
baseline within a minute.  Ivabradine is useful  to prevent abnormal increase in 
heart rate and minimizes  hypertension seen during laryngoscopy and 
endotracheal intubation.                                                                                                                  
 2)  Kunwar et al (34) in 2016 evaluated   the role oral Ivabradine on 
haemodynamics during laryngoscopy and intubation of trachea during general 
anaesthesia.They conducted the study in 50 ASA grade-I patients undergoing 
various procedures under general anaesthesia in two groups 25 each. Received 
oral Ivabradine 5mg one Tab. at 9.00 pm on the evening before the day of 
surgery and another one hour before intubation and the placebo. The result 
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was haemodynamic parameters were more stable in ivabradine is compared to 
Control group. Ivabradine is extremely useful drug to prevent the abnormal 
increase in rate of heart& blood pressure in the process of direct laryngoscopy 
and endotracheal intubation.                                                      
  3) Couvreur et al(35)  in 2010 was  investigated that  alterations  of 
left ventricular  work load and calcium control to prolonged heart rate 
reduction with ivabradine in reperfused heart .Rabbits were underwent 
occlusion of coronary artery for 20 minutes and reperfusion 0f heart was done 
for 3 weeks. For the period of reperfusion, rabbits received ivabradine (10 
mg/kg/day) or placebo (Control). Ivabradine decreased heart rate by around 
20% and improved both +35%   of ejection fraction&26% of systolic 
displacement after the interval of 3 weeks of treatment. Injection of a single 
i.v.bolus of ivabradine (1 mg/kg) in control group of rabbits at 3 weeks 
interval of reperfusion also considerably enhanced ejection fraction & systolic 
displacement. Prolonged heart rate drop protects the myocardium contrary to 
ventricular dysfunction stimulated by myocardial ischemia followed by 3 
weeks duration of reperfusion. Along with heart rate control, ivabradine has   
improved global and regional contractile function of the reperfused heart over 
a double mechanism concerning a direct mechanical influence and a long-term 
tolerance in calcium handling.  
 4) Cappato et al(36) in (2012) in have  evaluated “ the role of 
ivabradine in the treatment of symptomatic inappropriate sinus tachycardia 
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using  ivabradine”  .Because of its funny current channel blocking properties,  
selectively mitigate the high release of rate from S.A nodal cells in patients 
with increased heart rate. Twenty-one patients have been randomly divided in 
to 2 group. One group received placebo drug (10 patients) or ivabradine 5 mg 
2 times daily (10 patients)over a period of  6 weeks. After 6 weeks duration, 
patients   underwent symptom assessment and heart rate assessment at 
beginning and end of each phase. Ivabradine   group patients, relieved of 
symptoms of around 70%& with 47% of them felt whole elimination. These 
effects were accompanied with a significant decrease in heart rate at rest. .  
   5)  A.G.Shirbman et al (37) in 1987 (“The catecholamine and 
cardiovascular responses to laryngoscopy”). This study evaluated the effect of 
direct laryngoscopy &endotracheal intubation. This study was conducted in24 
patients were randomly divided into two groups. Premeditated with Inj. 
fentanyl and induced with Inj. thiopentone sodium, Inj. atracurium was 
injected and artificial ventilation given via  anatomical  face mask for 2 
minutes with 67% of nitrous oxide with 33%  oxygen. Subsequent to direct 
laryngoscopy, the vocal cords had been visualized for the duration of 10 
seconds. “Arterial pressure, heart rate and plasma noradrenaline and 
adrenaline concentrations were measured before and after induction and at 1, 3 
and 5 min after laryngoscopy”. Increases in arterial pressure & elevated 
concentrations of circulating catecholamine were found during   laryngoscopy 
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with or without intubation. Intubation was associated with significant 
increases in heart rate. There was no change in the laryngoscopy group. 
 6)  Sanjeev Singh et al(38) in 2013   evaluated “  the efficacy and 
safety of esmolol and lidocaine for suppressing cardiovascular response to 
laryngoscopy and tracheal intubation in a normotensive African population”.. 
This study was evaluated in 120 adult patients. They were ASA physical status 
I or II and posted for elective surgeries .Divided them into three groups, about 
40 patients in each group. First group patients has received no drug (control) 
as placebo, another group received 1.5 mg /kg I.V.Lignocaine and the third 
group received Inj.esmolol IV 2 mg/ kg 2 minutes prior to intubation. Mean 
arterial pressure and rate-pressure product were measured at preoperatively as 
baseline and after intubation at 1, 3, and 5minutes respectively.. After 
induction of with inj.thiopentalsodium and vecuronium bromide, the test 
solution was injected 2 min before endotracheal intubation. Alterations in 
haemodynamics were recorded .There was a rise in HR, SBP, DBP, MAP, and 
RPP from the base line in control group at 1 min with onward declines at 3 
and 5 min respectively after intubation.  They concluded that    Esmolol in the 
dose of 2 ml/kg can be given prophylactically to blunt the cardiovascular 
response to endotracheal intubation. 
  7)  Shruthi Jain et al (39) in 2015  investigated that Intravenous (IV)  
Lignocaine in bolus  dose during perioperative  period was infused to  blunt  
haemodynamic variations pertaining to intubation as well as extubation  in 
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elective laparoscopic cholecystectomies. This study was carried out in 60 
patients were divided into two groups of 30 each& gave bolus of 6 ml normal 
saline over 10 minutes duration followed by infusion of the same at 6ml/hr. 
and 2% lignocaine 1.5 mg/kg IV bolus (diluted to a volume of 6 ml with 
normal saline) for 10 minutes and after that an infusion at a rate of 1.5 
mg/kg/h The increase in heart rate and M.A.P are minimal in i.v .lignocaine 
group. (P < 0.05) during endotracheal intubation and during extubation. There 
was extended pain-less post-op duration of 5½ h as compared to 54.43 min in 
normal saline group (P < 0.05). 
 8)  Gulabaní et al (40) in 2015  compared  the efficacy of lignocaine 
with two different doses of dexmedetomidine for attenuating the 
haemodynamic changes. They conducted the study in 90 adults in the age 
group of 18-65 years of both sexes, were  normotensives assessed  as ASA 
Grade I or II, Divided into three groups. Group D1- IV Dexmedetomidine 
0.5μg/kg over 10 minutes, Group D2- IV Dexmedetomidine 1μg/kg over 10 
minutes and Group X- preservative free Lignocaine 1.5mg/kg diluted in 10 ml 
normal saline. They conclude that dexmedetomidine 1μg/kg adequately 
attenuated the cardiovascular response to direct laryngoscopy and 
endotracheal intubation when matched with dexmedetomidine 0.5μg/kg and 
lignocaine 1.5mg/kg.in pressor response to laryngoscopy and endotracheal 
intubation (ETI).  
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 9)  Malde and sarode et al (41)  in 2006 conducted a study to 
evaluate the effectiveness of Fentanyl (2µg/kg) - single bolus dose/intravenous  
Lignocaine (1.5 mg/kg) for attenuation haemodynamic changes in  90 patients. 
They received fentanyl /lignocaine / saline 5 minutes prior to endotracheal 
intubation.  
  The fentanyl group showed minimal increase in heart rate compared to 
lignocaine and Control group. The rise heart was persisted upto10 min in 
fentanyl, lignocaine & control groups respectively. The lignocaine group had 
minimal rise in systolic BP (12.1%) when compared to Control group (25.8%) 
(p=0.000) at endotracheal intubation& remained for 3 &10 minutes in both 
groups. The fentanyl group significantly reduced systolic BP after injection, 
which return back to normal at 1 - 3 minutes following endotracheal intubation 
and once again reduced after 4 minutes of endotracheal intubation. There was 
no side effects were noted in both groups. They concluded that “Lignocaine 
attenuated the rise in blood pressure with intubation whereas fentanyl 
prevented it totally”. 
 10)  Sarvesh P.sing et al (42) in 2010 evaluated the” efficacy of 
esmolol and labetalol, in low doses, for attenuation of sympathomimetic 
response to laryngoscopy and intubation.” This study was conducted in 75 
ASA physical status I and II adult patients, (18-45 yrs.) posted for elective 
surgeries and who required G.A and endotracheal intubation in three groups 
(25 each).Group C (control) 10 ml 0.9% saline i.v Group E (esmolol) 0.5 
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mg/kg added normal saline to make 10 ml i.v and Group L (labetalol) 0.25 
mg/kg added with normal saline to make10 ml i.v In the control group 10 ml 
of 0.9% saline was given both at 2 &5 min respectively  before endotracheal  
intubation. In the esmolol group 0.5 mg/kg of esmolol was given 2 minutes 
before and 10 ml of 0.9% saline 5 min before intubation. In the labetalol group 
10 ml of normal saline was administered 2 min before and 0.25 mg/kg of 
labetalol 5 min before endotracheal intubation. All the participants were 
exposed to the same standard anesthetic technique .Changes in 
haemodynamics have been recorded prior to induction, at time of endotracheal 
intubation and 1, 3, 5, and 10 min after intubation. M.A.P.and RPP were 
calculated. They also recorded abnormal ECG changes .They found that” 
esmolol (0.5 mg/kg), labetalol (0.25 mg/kg) significantly attenuated the rise in 
heart rate, systolic blood pressure, and RPP during laryngoscopy and 
intubation” and they are not statistically significant among the values for DBP 
and MAP in lower doses. They concluded that labetalol (0.25 mg/kg) better 
drug than esmolol (0.5mg/k 0 in attenuating the sympathomimetic response to 
direct laryngoscopy and endotracheal intubation.  
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AIM OF THE STUDY 
 
 To compare the efficacy of oral ivabradine and intravenous lignocaine 
to attenuate the hemodynamic response to laryngoscopy and endotracheal 
intubation 
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MATERIALS AND  METHODS 
 
 The study was conducted at Chengalpattu medical college   between   
2015- 2016. After obtaining ethical committee approval, 100 ASA І adult 
patients undergoing surgical procedures under general anaesthesia are 
randomly allotted into two groups  
STUDY DESIGN:       A Prospective randomized study  
SAMPLE SIZE:        100   patients were selected and allocated in two groups   
                                      Randomly. 50 patients in each group.         
INCLUSION CRITERIA: 
 ASA -I patients who were posted for various procedures under G.A. 
 Age group -20-45 years             
 Both sexes 
 Normal ECG 
 Mallampatti grading I&II 
EXCLUSION CRITERIA:  
 Patient Refusal 
 H/0 Chest pain /palpitations/syncope/H/o Respiratory problems, 
 Hepatic or renal problems 
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 Base line HR<60, base line systolic BP <100 mm Hg. 
 Patients with ECG abnormality 
 Patients with difficult airway 
PRE OP PREPARATION:   
 On the day of surgery Patients who satisfy the inclusion criteria were 
selected, written Informed consent obtained from all the patients.  Preoperative 
evaluation including detailed history, clinical evaluation, investigations and 
airway assessment were done. Intravenous canulation was done with 18G 
cannula after shifting the patient into the waiting area of the operation theater, 
and connected to a drip of Ringers lactate. 
PREMEDICATION:  
 Inj. Glycopyrrolate 0.2 mg I.M 45 Minutes before surgery and Inj. 
Ondensetron 4 mg sloe I.V and Inj. Fentanyl 2µg/kg before induction. 
MATERIALS USED: 
 Laryngoscope, Macintosh laryngoscope blades size 3&4 
 Appropriate size cuffed endotracheal tubes 
 Inj. Thiopentone Sodium 500mg vial 
 Inj. Succinylcholine 500 mg vial  
 Inj.Atracurium 25 mg ampule 
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 Inj.Lignocaine preservative free 
 Tab. Ivabradine 5 mg 
METHODOLOGY 
 Patients were randomly allocated into two groups, Test and Control 
[having 50  patients in each group]                   
 GROUP- I: received oral Ivabradine 5 mg one tab 2 hour before 
intubation and received 5 ml of normal saline 90 seconds before intubation.    
          GROUP-II: received Tab.B Complex 2 hours before intubation& I.V. 
Lignocaine 1.5 mg/kg 90 seconds before induction   
 These drugs were given by the anesthesiology residents who were not 
included in this study. 
Monitoring:   
 Continuous ECG, automated intermittent noninvasive blood pressure 
monitoring, Spo2 monitoring done.   
Pre oxygenation: 100% o2 for 3 min.     
Induction:    
 Inj.Thiopentone sodium 5 mg/kg I.v and succinylcholine 2 mg/kg I v. 
Inj .Lignocaine 1.5 mg/kg I.V (groupII). & Normal saline5ml (group I) given 
90 seconds before intubation. 
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 Intubation:     
 after 120 min intubation was achieved with appropriate size cuffed, 
endotracheal tube by the aid of Macintosh laryngoscope blade. Time for 
intubation did not exceed 20 sec.  
Maintenance:    
 Atracurium bisylate 0.5 mg/kg top-up dose. N2O:O2 in 2:1, 
intermittent positive pressure ventilation using circle absorber system 
connected to the Boyles machine. Surgery was not allowed to commence till 
the recordings were completed up to 10 min.     
 Parameters recorded were heart rate, systolic BP, diastolic BP, Mean 
arterial pressure. Ten minutes after intubation, after taking the recordings of 
hemodynamic parameters, inhalational agent was introduced into the 
anesthetic technique. 
Reversal:  
 Inj.Neostigmine 0.05 mg/kg and Inj.Glycopyrrolate 0.01 mg/kg. All 
patients were monitored for adverse effect effects of ivabradine in post op 
period. The recordings were noted at  
 preoperative (after premedication)  
 At induction 
 At intubation 
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 1 min after intubation 
 3min after intubation 
 5min after intubation 
 8 min after intubation 
 10 min after intubation. 
 30 min after intubation 
 1 hour after intubation 
 2 hours after intubation 
 4 hours after intubation 
 6 hours after intubation 
 12 hours after intubation 
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STATISTICAL ANALYSIS 
  
 Data were analyzed using SPSS16.0V.Software. Two sided 
independent students‟ t tests to analyze continuous data and chi square test for 
categorical data were used. P<0.05 was considered as statistically significant.  
DEMOGRAPHIC DATA    
 The two groups were comparable with respect to their age, weight, sex. 
There is no statistically significant difference among two groups in 
demographic profile.  
AGE 
 
GROUP N Mean Std. Deviation p value 
AGE 
 
Group I 50.00 34.24 9.290 
0.058 
Group II 50.00 30.82 8.535 
 
 The mean age in years was 34.24± 9.290 (Years) in group I and 30.82 ± 
8.535 (Years) in group II. There was statistically no significant difference 
between two groups   (p>0.05) 
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SEX   DISTRIBUTION 
  Group I Group II 
Male  12 15 
Female 38 35 
     
 In our series of 100 patients 27 were male and73 were females. 
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WEIGHT 
  GROUP N Mean Std. Deviation P value  
WEIGHT 
 
Group I 50.00 53.78 4.705 0.830 
 Group II 50.00 53.60 3.580 
 
 In our study mean Weight in kilograms was 53.78±4.705 (Kg) in group 
1 and53.60 ± 3.580(Kg) in group 2. There was statistically no significant 
difference between two groups(p>0.05) 
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                                                      HEART RATE 
 
GROUP N Mean 
Std. 
Deviation 
p value 
PRE OP 
 
Group I 50.00 77.10 7.947 <0.0001 
 Group II 50.00 88.38 7.214 
 AT 
INDUCTION  
Group I 50.00 79.34 7.657 
<0.0001 
  Group II 50.00 91.58 6.737 
AT 
INTUBATION 
Group I 50.00 76.74 7.575 
<0.0001 
  Group II 50.00 90.58 6.795 
1MIN AIT 
  
Group I 50.00 74.80 7.426 
<0.0001 
  Group II 50.00 87.60 9.532 
3MIN AIT 
  
Group I 50.00 73.40 7.253 
<0.0001 
  Group II 50.00 87.14 6.612 
5MINAIT 
  
Group I 50.00 72.08 7.182 <0.0001 
 Group II 50.00 85.56 6.181 
8 MIN AIT 
  
Group I 50.00 71.24 7.061 <0.0001 
 Group II 50.00 84.28 6.331 
10 MIN AIT 
  
Group I 50.00 70.74 6.866 <0.0001 
 Group II 50.00 83.38 5.966 
30 MIN  
  
Group I 50.00 70.82 6.492 <0.0001 
 Group II 50.00 84.70 5.776 
1 HOUR 
  
Group I 50.00 69.26 11.091 <0.0001 
 Group II 50.00 86.58 5.786 
2HOUR 
  
Group I 50.00 70.22 6.254 <0.0001 
 Group II 50.00 88.48 6.004 
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GROUP N Mean 
Std. 
Deviation 
p value 
4HOUR 
  
Group I 50.00 68.68 10.580 <0.0001 
Group II 50.00 90.76 5.546 
 
6HOUR 
  
Group I 50.00 68.40 10.508 <0.0001 
Group II 50.00 92.20 5.322  
<0.0001 12HOUR Group I 50.00 69.76 6.150 
 Group II 50.00 92..90 5.471  
 
 In our series. The mean heart rate of all patients in both groups were 
calculated and compared from pre- operative to up to 12 hours post-
operatively. The change in heart rate in group I and group II were statistically 
significant.            
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SYSTOLIC BLOOD PRESSURE 
  GROUP N Mean Std. Deviation P value  
PRE OP 
 
Group I 50.00 115.76 6.620 0.362 
  Group II 50.00 114.44 7.752 
 AT INDUCTION 
  
Group I 50.00 121.76 6.793 0.108 
  Group II 50.00 119.44 7.506 
AT INTUBATION 
  
Group I 50.00 119.40 6.540 0.226 
  Group II 50.00 117.68 7.542 
1MIN AIT 
  
Group I 50.00 117.02 6.653 0.327 
  Group II 50.00 115.60 7.722 
3MIN AIT 
  
Group I 50.00 114.66 6.675 0.392 
  Group II 50.00 113.44 7.500 
5MINAIT 
  
Group I 50.00 112.54 6.584 0.479 
  Group II 50.00 111.56 7.180 
8 MIN AIT 
  
Group I 50.00 110.98 6.268 0.450 
  Group II 50.00 109.96 7.140 
10 MIN AIT 
  
Group I 50.00 110.40 6.273 0.254 
  Group II 50.00 108.86 7.120 
30 MIN  
  
Group I 50.00 111.96 5.938 0.442 
  Group II 50.00 110.98 6.720 
1 HOUR 
  
Group I 50.00 113.62 5.678 0.763 
  Group II 50.00 113.98 6.206 
2HOUR 
  
Group I 50.00 114.98 5.408 0.119 
  Group II 50.00 116.70 5.534 
4HOUR 
  
Group I 50.00 116.86 5.718 
0.179 
  Group II 50.00 118.30 4.883 
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6HOUR 
  
Group I 50.00 118.68 5.332 
0.348 
  Group II 50.00 119.60 4.375 
12HOUR Group I 50.00 120.54 5.338 0.605 
 Group II 50.00 121.04 4.242  
 
 In our study series, mean systolic blood pressure was raised during 
induction and returned to preoperative level within 3 minutes of after 
intubation. Mean systolic pressures were within normal limits. There was 
statistically no significant difference between two groups (p>0.05) 
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DIASTOLIC BLOOD PRESSURE 
 GROUP N Mean Std. Deviation P value  
PRE OP 
 
GROUP I 50.00 69.86 5.548 
0.334 
GROUP II 50.00 68.60 7.301 
INDUCTION 
 
GROUP I 50.00 73.88 5.610 
0.503 
GROUP II 50.00 73.02 7.100 
INTUBATION 
 
GROUP I 50.00 71.72 5.620 
0.963 
GROUP II 50.00 71.66 7.050 
I MIN AIT 
 
GROUP I 50.00 69.92 5.721 
0.963 
GROUP II 50.00 69.86 6.966 
3 MIN AIT 
 
GROUP I 50.00 68.50 5.779 
0.888 
GROUP II 50.00 68.32 6.915 
5 MIN AIT 
 
GROUP I 50.00 67.22 5.604 
0.873 
GROUP II 50.00 67.02 6.784 
8 MIN AIT 
 
GROUP I 50.00 66.26 5.268 
0.960 
GROUP II 50.00 66.20 6.676 
10 MIN AIT 
 
GROUP I 50.00 65.90 5.108 
0.675 
GROUP II 50.00 65.40 6.673 
30 MINS 
 
GROUP I 50.00 67.02 5.332 
0.862 
GROUP II 50.00 67.24 7.170 
1 HOUR 
 
GROUP I 50.00 67.78 5.549 
0.908 
GROUP II 50.00 67.92 6.490 
2 HOURS 
 
GROUP I 50.00 68.56 5.350 0.476 
 GROUP II 50.00 69.38 6.094 
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4 HOURS 
 
GROUP I 50.00 70.06 5.024 
0.545 
GROUP II 50.00 70.74 6.107 
6HOURS 
 
GROUP I 50.00 71.28 5.507 
0.986 
GROUP II 50.00 71.26 6.141 
12HOURS 
 
GROUP I 50.00 72.78 5.144 
0.255 
GROUP II 50.00 71.50 6.011 
 
 In our study series, mean diastolic blood pressure was raised during 
induction and returned to preoperative level within 3 minutes of after 
intubation. Mean diastolic pressures were within normal limits. There was 
statistically no significant difference between two groups (p>0.05) 
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MEAN ARTERIAL PRESSURE 
  GROUP N Mean Std. Deviation P value  
PRE OP 
  
GROUP I 50.00 85.16 4.792 
0.279 
  GROUP II 50.00 83.87 6.869 
INDUCTION 
  
GROUP I 50.00 89.70 5.064 
0.313 
  GROUP II 50.00 88.51 6.588 
INTUBATION 
  
GROUP I 50.00 87.50 5.025 
0.648 
  GROUP II 50.00 86.97 6.568 
I MIN AIT 
  
GROUP I 50.00 85.51 5.058 
0.704 
  GROUP II 50.00 85.06 6.499 
3 MIN AIT 
  
GROUP I 50.00 83.74 5.484 
0.713 
  GROUP II 50.00 83.30 6.420 
5 MIN AIT 
  
GROUP I 50.00 82.33 5.004 
0.714 
  GROUP II 50.00 81.91 6.275 
8 MIN AIT 
  
GROUP I 50.00 81.16 4.737 
0.736 
  GROUP II 50.00 80.79 6.117 
10 MIN AIT 
  
GROUP I 50.00 80.76 4.654 
0.416 
  GROUP II 50.00 79.87 6.140 
30 MINS 
  
GROUP I 50.00 82.02 4.770 
0.863 
  GROUP II 50.00 81.82 6.334 
1 HOUR 
  
GROUP I 50.00 83.03 4.793 
0.812 
  GROUP II 50.00 83.28 5.643 
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2 HOURS 
  
GROUP I 50.00 84.06 4.717 
0.274 
  GROUP II 50.00 85.15 5.164 
4 HOURS 
  
GROUP I 50.00 85.62 4.678 
0.360 
  GROUP II 50.00 86.53 5.153 
6HOURS 
  
GROUP I 50.00 87.07 4.863 
0.815 
  GROUP II 50.00 87.31 5.089 
12HOURS 
  
GROUP I 50.00 88.70 4.479 
0.378 
  GROUP II 50.00 87.86 5.028 
 
  In our study series, mean arterial pressures were elevated. There was 
statistically no significant difference between two groups (p>0.05) 
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DISCUSSION 
 
 Rapid and dramatic hemodynamic changes are adversely affecting the 
patient. It may occur during perioperative period. Hypertension and 
tachycardia have been recognized since 1950‟s as commonly associated with 
intubation under light anaesthesia and is most evident during laryngoscopy 
and manipulation of epiglottis. The effect is temporary arising in 30 seconds 
after endotracheal intubation and lasts for less than 10 minutes thereafter. 
Sympathetic response to laryngoscopy has been studied and managed in 
past by topical anaesthesia of pharynx, superior laryngeal nerve block, tracheal 
spray of lignocaine, increasing the depth by inhalational agents, alpha and beta 
blockers, both alpha and beta blockers e.g. Labetalol, Nitroprusside, Calcium 
channel blockers, Nitroglycerine and strong narcotics etc. 
 “King et al in 1951 described pressor response to laryngoscopy and 
intubation in anaesthetised patients  ” (1) 
 In the present study, oral Ivabradine and intravenous Lignocaine were 
used to attenuate the haemodynamics. Blood pressure and heart rate response 
to direct laryngoscopy and endotracheal intubation was studied in both the 
groups. The pre-induction parameters of haemodynamic (i.e. after 
premedication) values were taken as basal values. After induction and 
intubation the surgeon was not allowed to operate till ten minutes (duration of 
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observation) because ivabradine has no analgesic properties and skin incision 
could have raised the heart rate and blood pressure giving false result. 
Heart Rate: 
 In our study, oral ivabradine reduces heart rate significantly than 
intravenous Lignocaine. Mean heart at intubation in oral ivabradine group 
(group I) was 76.74 ±7.575, whereas in group II mean heart rate at intubation 
was about 90.58± 6.795.  
 C. G. Raghu ram, Deep raj Singh, Aditya Vikram Kabra (1) observed 
that there was not a very significant rise in the heart rate in response to direct 
laryngoscopy and endotracheal intubation in  ivabradine group, when 
compared to the control group. There was a raise in heart rat returned to 
baseline within a minute. In the control group the baseline reading was high 
and the increase in pulse rate though decreased was above the normal value. 
 Kunwar et al (34) concluded that Ivabradine is a useful drug to blunt 
the abnormal increase in heart rate &blood pressure during direct  
laryngoscopy and  endotracheal intubation.   
Blood Pressure:    
  In our study, mean systolic blood pressure in group I  is  119 ±  6.540 
mmHg  during  intubation   and returned to  normal  within 3 minutes.  In 
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group II mean systolic blood pressure is 117.68 ± 7.542 & returned to normal 
within a minute. But there was no statistical significance between two groups. 
  The mean diastolic pressure during intubation is 71.72 ± 5.620 in group 
I  and 71.66±7.050  in  group II . There is a small raise in diastolic pressure 
during induction and come to base line within 3 minutes. 
 The mean arterial pressure during intubation is 87.50±5.025 in group I 
an86.97±6.56in group II. Mean arterial pressure was mildly elevated in both 
groups. There was no statistically significant change mean arterial pressure in 
both groups.  
  C. G. Raghu ram, Deep raj Singh, Aditya Vikram Kabra (1)found that 
oral Ivabradine minimizes  hypertension during laryngoscopy and 
endotracheal intubation.                                                                                
 Kunwar et al (34) evaluated that haemodynamic parameters were more 
stable in ivabradine and also it   prevents abnormal increase in heart rate & 
blood pressure during direct laryngoscopy and endotracheal intubation.                                                      
 Shruthi Jain et al (39) found that the increase in pulse rate &mean 
arterial pressure are less in i.v .lignocaine group during intubation as well as 
extubation. 
 Malde and sarode et al(41) evaluated the efficacy of single bolus doses 
of Fentanyl (2µg/kg) or Lignocaine (1.5 mg/kg) for attenuation haemodynamic 
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response that Lignocaine blunt the increase in blood pressure with 
endotracheal intubation. But fentanyl prohibited it totally. 
 Gulabaní et al (40) compared the efficacy of lignocaine with two 
different doses of dexmedetomidine for attenuating the pressor response and 
concluded that dexmedetomidine 1μg/kg adequately attenuated the 
hemodynamic response to laryngoscopy and endotracheal intubation when 
compared with dexmedetomidine 0.5μg/kg and lignocaine 1.5mg/kg. 
  C .D. Miller and S .J .Warren (43) used intravenous lignocaine to blunt 
the cardiovascular responses to direct laryngoscopy and endotracheal 
intubation. There was no significant change in   haemodynamics in I.V. 
Lignocaine group in that study. 
SIDE -EFFECTS: 
     All the patients in the study group were monitored for 12 hours. There 
were no side effects were found in the patients. 
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SUMMARY 
 
 “This Prospective randomised study was conducted to compare the 
effect of oral ivabradine and i.v lignocaine on the haemodynamics during 
laryngoscopy and endotracheal intubation in patients undergoing surgical 
procedures under general anaesthesia in 100 patients.50 patients in each group. 
Premedication, induction agent and muscle relaxant to facilitate intubation 
were standardized for both the groups. 
 In both groups surgery was not allowed for 10 minutes till the 
recordings were completed. Changes in heart rate, systolic blood pressure, 
diastolic blood pressure &mean arterial pressure were monitored. 
 According to this study significant changes in heart rate were observed.  
Heart Rate: Group I (oral Ivabradine) patients showed statistically significant 
change Heart rate.         
 Blood Pressure:  There was no statically significant change in blood 
pressure in both   Groups.   And also these patients were monitored post –
operatively for upto 12 hours. Side effects like bradycardia and visual 
disturbances   were not found in the patients. 
 Advantages of oral Ivabradine in this study is  
o Good attenuation of heart rate response 
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o  There was good heart rate control during perioperative period.  
o There was good heart reduction during extubation also.  
o The drug has minimal side effects. No side effects were 
observed during the study.  
o The drug is easily available& easy to administer. 
                  
 
 
 
 
 
 
 
 
 
 
84 
 
CONCLUSION 
 
 To conclude that  oral Ivabradine  has better heart rate control than 
Intravenous Lignocaine for  attenuation of haemodynamics  during 
laryngoscopy and endotracheal intubation in ASA I patients without side 
effects. 
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GLOSSARY: 
 PR   Pulse Rate 
 HR                   Heart Rate 
 M.A.P               Mean Arterial Pressure 
 SBP  Systolic Blood Pressure 
 DBP  Diastolic Blood Pressure 
 NIBP  Non invasive Blood Pressure 
 CVS  Cardiovascular System 
 RS  Respiratory System 
 CNS  Central Nervous System 
 WT  Weight 
 Kg                     Kilogram 
 Ml                    Milliliter 
 I.M                  Intra muscular 
 I.V.                  Intra Venous 
 Mg                    Milligram 
 ASA  American Society of Anaesthesiologist 
 MPC                Mallampatti Classification 
 AIT                  After Intubation 
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PROFORMA 
 Name : 
 Age  /sex: 
 IP no : 
 Date of admission : 
 Date of surgery : 
 Address for communication: 
 Contact no: 
 Diagnosis : 
 Surgery : 
 Weight : 
 PR: 
 BP: 
 CVS: 
 RS: 
 ABDOMEN: 
 CNS: 
 Mallampati classification class: 
 ASA PS class : 
 Investigations : 
 Hb: 
 TC 
 DC 
93 
 
 Platelets 
 RFT: 
 Urine routine: 
 ECG: 
 CXR: 
 Electrolytes: 
 Others : 
 Premedication : 
 Pre oxygenation: 
  Induction drugs given : 
 Intubation: 
  Hemodynamic monitoring :PR , Systolic BP ,Diastolic BP ,Mean 
arterial BP are recorded at 
TIME  PR Systolic  BP Diastolic BP Mean 
Arterial 
Pressure 
Preoperative     
At induction     
At Intubation     
1min AIT     
5min AIT     
8min AIT     
10min AIT     
30min AIT     
1 Hour     
2 Hours     
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4 Hours     
6 Hours     
12 Hours     
 
 Maintenance: 
 Relaxation: 
 Reversal:  
  Extubation  
  Other side effects: 
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